Evaluation of tumor-associated antigen (2H6 antigen) in detecting early stages of gastric cancer.
A sandwich enzymed-linked immunosorbent assay (ELISA) was developed by using monoclonal antibody 2H6 (2H6 MoAb). MoAb 2H6 could be used to detect the 2H6 antigen in the sera of several cancers, showing positive rates of 65.4%, 66.7%, 47.4%, 80.0%, 45.2% and 16.7% in gastric cancer, hepatocellular carcinoma, cancers of the colon, esophagus, breast and pancreas, respectively. On the other hand, the positive rates in benign diseases or healthy donors were 3.4%, 3.4%, 4.2%, 8.3%, 6.9%, and 1.2% in myasthenia gravis, polymyositis, gastritis, gastric ulcer, other benign diseases and normal healthy donors, respectively. Fifty-two patients with gastric cancer were investigated in detail. The positive rates of serum 2H6 antigen, CEA, AFP, CA19-9 and CA125 in patients with gastric cancer were 65.4%, 9.6%, 2.3%, 25.0% and 8.1%, respectively. Among these tumor markers, serum 2H6 antigen levels alone were significantly elevated in patients with early stage (I and II) gastric cancer. Furthermore, combining the measurement for serum 2H6 with CA19-9 increased the percentage of gastric cancer slightly. No correlation between 2H6 antigen and these other tumor markers was observed. The serum levels of 2H6 antigen were monitored post-surgically in 11 patients for 12 weeks and they were found to diminish gradually. The findings suggest that the measurement of serum 2H6 antigen may be a useful marker for an early stage of gastric cancer.